Lantheus wins FDA approval for PYLARIFY TruVu and beats Q1 2026 estimates
Lantheus wins FDA approval for PYLARIFY TruVu and beats Q1 2026 estimates with revenue $377.3M, adjusted EPS $1.46
- FDA approval of PYLARIFY TruVu was disclosed in a recent Lantheus SEC filing.
- Q1 2026 revenue of $377.3 million exceeded the Zacks consensus estimate of $358.1 million.
- Q1 2026 adjusted EPS of $1.46 beat the Zacks consensus estimate of $1.25.
- Company reaffirmed full-year 2026 revenue and earnings guidance following the Q1 2026 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.